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Abstract
Background There are many controversies surrounding the
effectiveness of endoscopic treatment of vesicouretheral re-
flux (VUR) in children, thus it is of highest priority to analyze
factors influencing the outcome of therapy and to search for
new methods that would increase the success rate and reduce
the number of reinjections.
Objective The aim of the study was to analyze whether intra-
operative contrast-enhanced urosonography (ce-US) may in-
crease the effectiveness of endoscopic anti-reflux therapy.
Materials and methods Intraoperative contrast-enhanced
urosonography (ce-US) with SonoVue® was performed in
17 patients (25 ureteral units) undergoing endoscopic treat-
ment of VUR. Ce-US was performed in the operating room
before the procedure and after injection of the bulking mate-
rial. When VUR persisted, the operator repeated the injection,
which was followed by ce-US. The results were compared
with those obtained from a control group (15 patients; 22
ureteral units).
Results A repeat injection during a single endoscopic treat-
ment was required in 24% of cases. The overall success rate
confirmed at 6–12 months’ follow-ups was 84%. The success
rate was significantly higher in comparison to the control
group (success: 64%).
Conclusion Intraoperative ce-US performed during endo-
scopic treatment of VUR enables immediate monitoring of
outcome and provides the opportunity for repeat injection
during the same procedure, thus increasing the efficacy of
the procedure and reducing the number of reinjections.
Keywords Intraoperative ultrasound . Urosonography .
Contrast enhancement . Endoscopic surgery . Vesicoureteral
reflux . Child
Introduction
Endoscopic injection of bulking agents is one of the methods
of treatment of vesicoureteral reflux (VUR) in children, next
to long-term antibiotic prophylaxis and open anti-reflux sur-
gery. Owing to a number of benefits such as minimal inva-
siveness, high efficacy, low complication rate and reduced
cost due to short operative time and short hospital stay, it has
recently gained great popularity [1]. Following the develop-
ment and improvement of injection techniques, recent studies
have shown higher success rates of endoscopic treatment than
open surgery in the treatment of patients with intermediate and
high-grade VUR [1, 2]. However, a meta-analysis including
63 studies has demonstrated that the rate of success of endo-
scopic treatment decreases as the reflux grade increases, from
78.5% in grades I and II down to 51% in grade V [3]. As the
volume of the injected material decreases in long-term follow-
up, the rate of success also decreases with time from 93% at
1 month after the injection to even 35% after 1 year [4]. There
remains controversy regarding the effectiveness of endoscopic
treatment, thus it is of high priority to analyze factors influenc-
ing the outcome of such therapy and to search for new
methods that would increase the success rate, reduce the
Electronic supplementary material The online version of this article
(doi:10.1007/s00247-014-2963-7) contains supplementary material,
which is available to authorized users.
M. M. Woźniak (*) :A. Pawelec :A. Brodzisz :A. P. Wieczorek
Department of Pediatric Radiology, Medical University of Lublin,
Al. Racławickie 1, 20-059 Lublin, Poland
e-mail: mwozniak@hoga.pl
P. Osemlak : P. Nachulewicz
Department of Pediatric Surgery and Traumatology,
Medical University of Lublin, Al. Racławickie 1, Lublin, Poland
M. M. Zajączkowska
Department of Pediatric Nephrology, Medical University of Lublin,




Received: 3 December 2013 /Revised: 25 January 2014 /Accepted: 5 March 2014 /Published online: 10 April 2014
number of reinjections required and reduce the risk of
paravasation or post-interventional ureteric obstruction.
The aim of the current study was to analyze whether
intraoperative contrast-enhanced urosonography (ce-US)
could be a useful tool for increasing the effectiveness of
endoscopic anti-reflux therapy due to immediate monitoring
of its outcome during the operation without the risk of radiat-
ing imaging such as fluoroscopy and the possibility of repeat
injection during a single endoscopic treatment.
Materials and methods
Patients
A prospective nonrandomized preliminary study approved by
the Research Ethics Committee was performed between De-
cember 2011 and October 2013 and informed consent was
given by the parents of all participants. Intraoperative ce-US
with the off-label use of the US contrast agent SonoVue®
(Bracco, Milan, Italy) was performed in 17 consecutive pa-
tients undergoing endoscopic injection of bulking agents into
the submucosa of the 25 ureteral openings in patients treated
for vesicoureteral reflux. The mean age of patients was 4 years
and 6 months, ranging from 4 months to 15 years and
8 months. The study group consisted of 16 girls and one
boy. The inclusion criteria were recurrent urinary tract infec-
tions (UTIs) diagnosed on the basis of clinical symptoms and
positive urine culture coexisting with vesicoureteral reflux
diagnosed with previously performed contrast-enhanced
voiding urosonography (ce-VUS). The exclusion criteria in-
volved coexisting abnormalities of the urogenital tract, in
particular ureterocele, ectopic ureters, posterior urethral
valves, neurogenic bladder due to myelomeningocele and
urge incontinence. All patients were monitored for adverse
reactions to the contrast agent.
The control group was retrospective and consisted of 15
consecutive patients and 22 ureteral units and included 10
girls and 5 boys undergoing endoscopic injection of bulking
agents into the submucosa in a standard protocol, without
monitoring by intraoperative ce-US, between July 2009 and
December 2011. The mean age of the controls was 3 years and
9 months, ranging from 5 months to 13 years and 2 months.
The inclusion criteria were similar as for the study group, e.g.,
recurrent UTIs diagnosed on the basis of clinical symptoms
and positive urine culture coexisting with vesicoureteral re-
flux diagnosed with previously performed voiding
cystourethrography (VCUG). The exclusion criteria involved
congenital abnormalities of the urogenital tract, similarly as in
the study group. VCUG examinations were performed on an
outpatient basis. The contrast agent was administered through
the catheter via gravity. Anteroposterior imaging of the blad-
der was performed during early filling. When bladder filling
was complete, steep oblique images centered on the
ureterovesical junctions were obtained during voiding. Then
the anteroposterior image was performed after voiding was
completed.
All patients (n=32) underwent uroflowmetry with post-
void residual assessment prior the endoscopic anti-reflux ther-
apy to exclude bladder outlet obstruction as the potential cause
of the VUR.
Procedure
All 32 patients from both the study group (n=17) and control
group (n=15) underwent endoscopic dextranomer/hyaluronic
acid (Deflux®; Salix Pharmaceuticals, Uppsala, Sweden) in-
jection by subureteric transurethral injection. Endoscopic
treatment was carried out as day surgery, with the patients
under general anesthesia. Patients received parenteral antibi-
otic prophylaxis before and after subureteric transurethral
injection. The operative technique comprised a subureteric
transurethral injection of bulking material with a pediatric
cystoscope when the bladder was semi-filled to allow for good
visualization of the ureteral orifice and to avoid tension within
the submucosal layer of the ureter secondary to
overdistension. A 20-gauge needle was inserted 2 to 3 mm
proximal to the ureteral orifice and delivered the bulking
material underneath the ureter at the 6 o’clock position. The
injection proceeded until a “bulge” with an orifice with an
elevated, inverted crescent shape was obtained [5]. In both
groups, the injected volume varied from 0.5 to 1.3 mL per
ureteral unit and was determined according to the age of the
patient, shape of the ureteral orifice and the grade of VUR.
The volume was recognized as sufficient if the visual assess-
ment performed by the operator was recognized as satisfacto-
ry, e.g., if the ureteric orifice was lying on the top of the
mountain-shaped bolus. The mean injected volume of bulking
agent per renal unit was 0.9 mL in both groups. After the
injection, the needle was kept in position for 15–30 s to
prevent extrusion of bulking agent. Success of operation was
defined as downgrading to grade 0, while failure was defined
either as VUR persistence at the same level or decrease of
VUR grade. All procedures in both groups were performed by
the same operator with 15 years of experience in pediatric
urology. The operator was experienced in subureteric trans-
urethral injection, using the same operation technique.
In the patients from the study group (n=17) the procedure,
was monitored by intraoperative urosonography (Fig. 1). Ce-
US was performed with the use of a Philips iU22 ultrasound
scanner 3–5MHz transducer using the contrast imaging mode
and two-dimensional, side-to-side (grey scale to contrast)
technique, according to recommendations for pediatric
uroradiology from the Uroradiology Task Force of the Euro-
pean Society of Pediatric Radiology, PediatricWorking Group
of the European Society of Urogenital Radiology and results
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published by other authors [6–8]. At present, ce-US in chil-
dren can only be performed off-license; however, the authors
decided for the off-label use of US contrast agent since, from a
medical and scientific perspective, pediatric ce-US should be
promoted [6]. A solution of 2.4 ml of the US contrast agent
SonoVue® (Bracco, Milan, Italy) and saline (0.9% NaCl) was
administered slowly through a catheter (Nelaton, 6–10 F) into
the bladder under continuous sonographic monitoring of the
bladder and terminal ureters until the maximum bladder ca-
pacity was reached while the patient was in the supine posi-
tion. Subsequently, the catheter was removed and the bladder
was emptied. Then the pediatric cystoscope was inserted and
the bladder was semi-filled with the solution of saline to
perform subureteric transurethral injection. After the bulking
agent injection, the bladder was emptied through a cystoscope
and the solution of contrast was administered via cystoscope.
If the result of the bulking agent injection was not satisfactory
the procedure was repeated in the same manner. Overall, ce-
USwas performed in the operating roomwhile the patient was
still anesthetized, either twice or in some patients three times:
1) before the procedure to confirm the presence of VUR, 2)
after the injection of the bulking material to assess the efficacy
of treatment and 3) after the repeat injection of bulking agent
performed in cases when VUR persisted following the initial
injection of bulking material (Fig. 2). The patient was cathe-
terized only for the first ce-US. Subsequent ce-US procedures
were performed after the contrast solution administration
through the cystoscope. The repeat injection of bulking mate-
rial was delivered underneath the ureter at the 9 o’clock and/or
3 o-clock position until a “bulge” in the orifice was obtained.
Contrast bubbles persisting in the urinary tract from previous
ce-US studies were destroyed with the use of the high-MI
Power Doppler mode before subsequent fresh administration
of contrast solution. All patients were carefully monitored for
adverse reactions during all procedures.
All intraoperative ce-US examinations were performed by
the same pediatric radiologist with 12 years of experience in
pediatric radiology and uroradiology, including ce-VUS.
Statistical analysis
Statistical analysis was performed using Statistica® (StatSoft,
Tulsa, USA) software, version 10.0. The study group and
control group were compared in terms of age, sex, occurrence
of infections, reflux grade and the volume of the bulging agent
injected using the student t- and the chi-square tests.
Results
Low-pressure (“passive”) VUR was diagnosed in patients in
the study group (n=17), being unilateral in nine patients and
bilateral in eight patients. Among the 25 treated ureteral units,
the following grades of VUR were identified: grade II in 3
ureteral units (12%), grade III in 14 ureteral units (56%), grade
IV in 6 ureteral units (24%) and grade V in 2 ureteral units
(8%). Out of 17 patients, 14 were diagnosed preoperatively
based on VCUG and three patients based on ce-VUS. Among
pathogens causing the infections the following species of
bacteria were found: Escherichia coli, Pseudomonas
aeruginosa and Proteus species, at levels ranging from 105/
ml to 107/ml.
The control group included 15 children with VUR, which
was unilateral in 8 children and bilateral in 7 children. Among
Fig. 1 Intraoperative ce-US
performed during endoscopic
Deflux® injection by subureteric
transurethral injection carried out
as day surgery, with the patients
under general anesthesia
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22 treated ureteral units the following grades of VUR were
identified: grade II in 5 ureteral units (23%), grade III in 10
ureteral units (45%) and grade IV in 7 ureteral units (32%). All
15 patients were diagnosed preoperatively based on VCUG.
There was no statistically significant difference between
the study group and control group in terms of age, occurrence
of infections, reflux grade and the volume of the bulging agent
injected (P>0.05). There was statistical difference between
the groups when sex was compared, as the control group
included more boys than the study group (5 vs. 1), which
resulted from the fact that the patients were included
consecutively.
Immediate intraoperative results
In the 17 patients undergoing endoscopic injection of bulking
agents 25 ureteral units were treated. A single injection of
bulking material was sufficient in 19 (76%) ureteral units to
obtain success. Success after the second injection performed
during the same operation due to persistence of VUR was
Fig. 2 Intraoperative contrast-
enhanced urosonography (ce-
US). Two-dimensional US in
contrast imaging side-to-side
mode (contrast image on left side,
fundamental mode on right side).
a Ce-US performed before
endoscopic treatment shows
right-side low-pressure (passive)
VUR grade IV (arrows). b Ce-US
performed after the first injection
of bulking material shows
downgrading of the right-side
VUR to grade III (arrows). c Ce-
US performed after the second
injection of bulking material
shows no VUR on the right side
(arrows)
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achieved in three ureteral units (12%). The overall success as
assessed with intraoperative ce-US was 88% per ureteral unit.
The success rates in grades II, III, IVand V were 100%, 93%,
83% and 50%, respectively. Failure was observed intraopera-
tively in three (12%) ureteral units (grades III, IV and V), in
which even repeat injections of bulking agent did not stop the
VUR. In these patients, the ostia were placed laterally, out of
the bladder trigon. Altogether, the need for a second injection
was observed in six ureteral units (24%) (successful in 3
ureteral units, failed in 3 ureteral units). The results are pre-
sented in Table 1. No adverse reactions to US contrast agent
were noted.
Follow-up
Follow-up examinations were performed in all patients 6–
12 months after the endoscopic treatment, including the study
group and the control group. The children from the study
group underwent follow-up ce-VUS, whereas the children
from the control group were followed up by VCUG.
In the study group (25 ureteral units), follow-up ce-VUS
showed overall success in 21 (84%) ureteral units and failure
in 4 (16%). The success rates in grades II, III, IV and V were
100%, 100%, 50% and 50%, respectively. In the group in
which treatment was considered to have failed, only high-
grade VUR was observed: grade IV in three ureteral units
and grade V in one unit.
In the control group (22 ureteral units), follow-up VCUG
showed complete success in 14 (64%) ureteral units and
failure in 8 (36%) ureteral units (Table 2). The success rates
in grades II, III and IV were 60%, 70% and 57%, respectively.
Discussion
The results obtained in this preliminary study show that repeat
injection of bulking agent during endoscopic treatment of
VUR was needed in 24% of cases when VUR persisted after
the first injection. The overall success rate confirmed by
follow-up examination performed 6 to 12 months after
surgery in the study group was significantly higher than in
the control group (84% vs. 63.64%). The overall success rate
observed intra-operatively was even higher (88%), with the
exception of grade III ureteral units, where intraoperatively a
92.85% success rate was observed, while follow-up showed a
100% success rate. This can be explained either by the bulging
agent undergoing a stabilization process with time and sealing
the orifice or by natural subsiding of VUR. However, the
authors believe that the final effect should be measured in a
long-term follow-up up to 5 years following the procedure [9].
With the use of newly available bulking agents it is a
reliable and safe alternative to open ureteral reimplantation
for the treatment of VUR in children [10]. Since the market for
various bulking agents has developed in recent years and the
experience of operators has significantly increased over the
last decade, endoscopic treatment may become the new gold
standard for surgical correction of VUR. However, increasing
the effectiveness of endoscopic treatment of children suffering
from VUR continues to be a challenge. Various authors have
attempted to identify the factors influencing the success rate of
endoscopic treatment of VUR.Modifications of the procedure
may also play an important role in achieving even better
results. The current study belongs to this group, being an
attempt to evaluate whether modification of the subureteric
transurethral injection technique with implementation of in-
traoperative monitoring enabling repeated injection of bulking
material during the same procedure would increase the suc-
cess rate and reduce the need for repeat operations/
interventions.
Kajbafzadeh et al. [11] attempted to identify independent
factors that could predict VUR resolution after endoscopic
treatment using dextranomer/hyaluronic acid copolymer
(Deflux®; Salix Pharmaceuticals, USA) in children free of
anatomical anomalies. The study showed that successful
VUR correction after the endoscopic injection of Deflux®
can be predicted with respect to preoperative VUR grade and
presence of mound after operation. A similar study was per-
formed byAlkan et al. [12]. The authors attempted to clarify the
factors affecting the success rate of endoscopic subureteral
injection of VUR, concluding that the procedure provides a
Table 1 The results of endoscopic treatment of vesicouretheral reflux (VUR) obtainedwith intraoperative contrast-enhanced urosonography in the study
group
Study group Success rate of first injection
of bulking material




Grade Number of ureteral
openings
% Grade Number of ureteral
openings
% Grade Number of ureteral
openings
% Grade Number of ureteral
openings
%
II 3 25 100% II 3 19 76% II 0 3 12% II 0 3 12%
III 14 III 12 III 1 III 1
IV 6 IV 3 IV 2 IV 1
V 2 V 1 V 0 V 1
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high success rate for the treatment of VUR, which decreases to
grade Vand the presence of bladder exstrophy. A single injec-
tion of various materials was found to be successful in most
patients with grade II VUR, whereas grade IV and III patients
required repeat injections that resulted in 100% and 94% suc-
cess rates, respectively. These results are consistent with the
results obtained herein, where the overall success rate in the
study group was 84% and the success rates defined intraoper-
atively in grades II, III, IVand V were 100%, 92.85%, 83.33%
and 50%, respectively; success rates at follow-up were 100%,
100%, 50% and 50% for these grades, respectively.
Elder et al. [3] performed a meta-analysis of the existing
literature comparing the results of endoscopic treatment and
open surgical correction. The analysis, which included 5,527
patients and 8,101 renal units, showed that the reflux resolu-
tion rate (by ureter) following one treatment was 78.5% for
grades I and II reflux, 72% for grade III, 63% for grade IV
63% and 51% for grade V. If the first injection was unsuc-
cessful, the second treatment had a success rate of 68%, and
the third treatment had a success rate of 34%. The aggregate
success rate with one or more injections was 85%, similar to
the results obtained herein (84%), with the major difference
being that the repeat injection in our study was performed
during the same endoscopic treatment. In another study, Elder
et al. [3] examined the use of endoscopic injection with
dextranomer/hyaluronic acid copolymer as a curative option
and as an alternative to antibiotic prophylaxis, concluding that
the treatment with endoscopic injection of Dx/HA resulted in
significantly fewer urinary tract infections than in children
receiving antibiotic prophylaxis [13]. In the study by Garcia-
Aparicio et al. [9], the authors demonstrated that in both short-
and long-term follow-ups multiple endoscopic treatment of
VUR grades II, III and IV was as effective as ureteral
reimplantation.
Pichler et al. [14] evaluated whether real-time 3-D-
ultrasound together with clinical evaluation could be used as
an alternative to VCUG after endoscopic treatment of VUR in
children at postoperative follow-up. The authors reported that
3-D-US seems to be sufficient after endoscopic treatment of
low-grade VUR, while VCUG should be performed when the
depot has shifted, and that invasive investigations are unnec-
essary in asymptomatic children with orthotopic bulk. In this
study all patients underwent follow-up examinations 1 day
and 3, 9 and 18 months following treatment. In the modified
algorithm suggested in the herein study, owing to the use of
intraoperative ce-US during endoscopic treatment, the patients
can avoid the follow-up VCUG in the early postoperative
period, which seems to benefit the children, aside from all
the other advantages of the method. Ce-VUS also appeared to
be a reliable diagnostic tool in the follow-up of children
undergoing anti-reflux endoscopic treatment [14].
Predicting the outcome of the operation is an important
issue, thus Parente et al. [15] evaluated the accuracy of sur-
geons’ intraoperative observations as a predictor of treatment
results. They concluded, however, that the surgeon’s opinion
is not an accurate tool to predict the outcome of endoscopic
treatment of VUR [15]. Intraoperative ce-US seems to be a
promising tool allowing prediction of the final outcome with a
higher accuracy than the operator’s opinion by itself.
In the current preliminary study the authors attempted to
evaluate whether modification of the standard subureteric
transurethral injection endoscopic treatment with bulking
agents of VUR, involving the implementation of intraopera-
tive ce-US that enabled the repeated injection of bulking
material during the same procedure, would help to increase
the success rate. The study group and the control group were
comparable in terms of age, occurrence of infections, reflux
grade and the volume of the bulging agent injected, and
implementation of intraoperative ce-US resulted in a higher
success rate in the study group. The preliminary results show
that this modification has the potential to increase the success
rate and reduce the number of reoperations.
Table 2 The results of long-term endoscopic treatment of vesicouretheral reflux (VUR) obtained at follow-up examinations performed 6–12 months
following treatment in the study group and control group
Success Failure
Grade Number of ureteral openings % Grade Number of ureteral openings %
STUDY GROUP
II 3 21 84% II 0 4 16%
III 14 III 0
IV 3 IV 3
V 1 V 1
CONTROL GROUP
II 3 14 64% II 2 8 36%
III 7 III 3
IV 4 IV 3
V 0 V 0
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The authors realize that the study has got limitations. A
small number of patients in the study group is a major one.
Another limitation recognized by the authors is the off-label
use of the agent. The authors, however, support the position
expressed by the European Society of Paediatric Radiology
Uroradiology Task Force and European Society of
Uroradiology Paediatric Working Group promoting pediatric
ce-US [6]. In herein study no adverse reactions were noted
similarly as in other studies performed in pediatric popula-
tions. A questionnaire-based European survey, in which data
from our center were also included, demonstrated around
4,000 intracavitary (mostly intravesical) pediatric applications
of US contrast without any reported major adverse reactions,
which was also confirmed in another recent study including
1,010 children [16, 17]. Moreover, performing ce-VUS in-
stead of VCUG in the pediatric population could help signif-
icantly reduce the exposure of this group of patients to diag-
nostic radiation [6, 8, 17–19]. Another important limitation is
lack of randomization and the fact that the study group was
prospective while it was compared to the control group, which
was retrospective. Using a retrospective control group resulted
also in the fact that the study group was diagnosed and
followed up in ce-VUS while the control group follow-up
was in VCUG. It is an important limitation as there is a
difference between VCUG and ce-VUS in terms of sensitivity,
i.e. on average 10% more VURs are detected with ce-VUS in
comparison to VCUG and ce-VUS detects more slightly
higher-grade VURs than VCUG [20]. Another important is-
sue is the fact that intraoperative ce-US lacks detection of
high-pressure VUR as it would occur only during voiding,
which is not achievable in the anaesthetized child. Similarly,
the evaluation of the urethra during voiding is not possible,
unlike during ce-VUS [20, 21]. Thus, the study should be
treated as a preliminary report and requires further studies on a
larger population of patients.
Conclusion
Intraoperative ce-US performed during endoscopic injection
of bulking agents enables immediate monitoring of the effect
of endoscopic treatment and provides the opportunity for
repeat injection of bulkingmaterial during a single endoscopic
treatment, increasing the efficacy of the procedure and reduc-
ing the number of re-injections required. In comparison to the
control group the results obtained show that the method en-
ables a significantly higher success rate. Additionally, it en-
ables a more precise prediction of the final outcome of the
operation while still in the operating room. However, the long-
term clinical results of endoscopic treatment should be evalu-
ated with a follow-up of at least 5 years after the operation.
Further studies on larger populations are mandatory.
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